Stephen Knight

Stephen Knight is a prominent figure in the healthcare and biotechnology investment sector. He currently serves as the President and Managing Partner at F-Prime Capital, a position he has held since joining the firm in 2003.34

Professional Background

Stephen Knight has over 30 years of experience in the pharmaceutical and biotechnology industries.3 His career includes:

• President and Managing Partner at F-Prime Capital (2003-present)4
• President and COO at EPIX Pharmaceuticals (1996-2003)4
• Consultant at Arthur D. Little (1991-1996)4
• Junior Researcher at AT&T Bell Laboratories (1985)4

Education

Knight holds impressive academic credentials:

• M.D. from Yale University School of Medicine (1990)24
• M.B.A. from Yale School of Organization and Management (1990)24
• B.S. in Biology from Columbia University, graduating summa cum laude and Phi Beta Kappa (1983)24

Role at F-Prime Capital

At F-Prime Capital, Stephen Knight:

• Invests broadly across healthcare2
• Serves on the Board of Directors for several companies, including Atalanta Therapeutics, Leyden Labs, Paradigm, Quantum Circuits, Inc. (QCI), Skyline Therapeutics, and Xaira Therapeutics3
• Has previously served on boards of notable companies such as Beam Therapeutics, Blueprint Medicines, and Denali Therapeutics3

Investment Focus

Under Knight's leadership, F-Prime Capital:

• Manages over $4.5 billion in assets1
• Has a global portfolio of over 300 companies1
• Focuses on healthcare (therapeutics, medtech, health IT) and technology (enterprise software, fintech, frontier tech)1
• Has created or co-created over 30 companies, including Beam Therapeutics and Denali Therapeutics1

Stephen Knight's expertise and leadership have significantly contributed to F-Prime Capital's success in identifying and supporting innovative companies in the healthcare and technology sectors.